Treatment response to LPV/r-based HAART in HIV-infected patients aged >60 years-data from the STAR/STELLA cohorts

Purpose of the study : In Germany, older age is described as a risk factor for late presentation of HIV disease (defined as 60 y and 31%-49% in the younger age groups (see Table 1). Across age groups, 43%-60% of pts had pretreatment HIV1-RNA levels >100,000 c/mL. Median times to virologic response (Figure 1) and response rates at week 48 did not differ across age groups in either analysis, nor did immunologic outcomes. Median times to +100/μL CD4 increase were between 11.1 and 15.3 weeks. CD4 increase at week 48 was lower in pts >60 y compared to patients of younger age categories (165/μL vs 211/μL; P=ns). However, these differences between age groups did not reach statistical significance, even when stratified by baseline CD4 count 60 y group (P=0.194). In addition, 11.3 % of pts ≤60 and 14.9% of pts >60 y discontinued therapy prior to week 48 due to treatment related AEs (P=0.427). Conclusions: In the STAR/STELLA cohorts, pts aged >60 y had high rates of late presentation, with two-thirds of patients with CD4 cell counts <200/μL. Nevertheless, older pts did not differ significantly from younger pts regarding immunologic and virologic response after initiation of LPV/r-based therapy. (Published: 11 November 2012) Citation: Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection Koegl C et al. Journal of the International AIDS Society 2012, 15 (Suppl 4):18297 http://www.jiasociety.org/index.php/jias/article/view/18297 | http://dx.doi.org/10.7448/IAS.15.6.18297